Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects
Thomas Southworth, Natalie Jackson, Dave Singh
Abstract
Chronic obstructive pulmonary disease (COPD) patients have a higher risk of developing severe illness and mortality following severe acute respiratory coronavirus 2 (SARS-COV-2) infection [1]. Vaccination protects against coronavirus disease 2019 (COVID-19) through the development of systemic and airway immune responses. Patients with COPD display altered humoral immunity, with reduced antibody responses compared to healthy controls (HC) [2, 3]. We studied SARS-COV-2 vaccine specific immune responses in COPD patients versus HC, using systemic, nasal and sputum samples.
Topics & Concepts
MedicineCOPDImmune systemImmunologySputumVaccinationCoronavirusImmunityAirwayAntibodyRespiratory systemDiseaseCoronavirus disease 2019 (COVID-19)Internal medicineInfectious disease (medical specialty)TuberculosisPathologySurgeryRespiratory viral infections researchInfluenza Virus Research StudiesSARS-CoV-2 and COVID-19 Research